Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 489-491, November 2009

Can we do better in developing new drugs for Alzheimer's disease?

  • Serge Gauthier

      Affiliations

    • Department of Psychiatry, Neurology & Neurosurgery, McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationCorresponding author. Tel.: 514-766-2010; Fax: 514-888-4050.
    • ,
  • Philip Scheltens

      Affiliations

    • Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S1552-5260(09)02284-5

doi:10.1016/j.jalz.2009.09.002

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 6 , Pages 489-491, November 2009

Article Tools